U.S. Markets close in 5 hrs 6 mins

Glaxo Stops MAGE-A3 Lung Cancer Study

Zacks Equity Research

GlaxoSmithKline’s (GSK) shares fell 0.56% after the company announced that it has decided to terminate the phase III MAGRIT study on its MAGE-A3 cancer immunotherapeutic. We note that Glaxo has a collaboration agreement with Agenus Inc. (AGEN) for the candidate. Agenus shares tumbled 3.02% on the news.

The randomized, blinded, placebo-controlled study evaluated the efficacy and safety of the MAGE-A3 cancer immunotherapeutic in patients suffering from stage IB, II and IIIA completely resected non-small cell lung cancer (:NSCLC), whose tumors expressed the MAGE-A3 gene. Glaxo decided to stop the study after it was found impossible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the MAGE-A3 cancer immunotherapeutic.

We remind investors that just a few weeks back, Glaxo had reported disappointing data from this study. The data from the MAGRIT study revealed that MAGE-A3 cancer immunotherapeutic did not significantly extend disease free survival (DFS) in both the overall MAGE-A3 positive population and in MAGE-A3-positive patients who did not receive chemotherapy as compared to placebo. At that time, Glaxo decided to continue with the MAGRIT study to assess the third co-primary endpoint.

We note that MAGE-A3 cancer immunotherapeutic is also being evaluated for stage IIIB/C melanoma with macroscopic nodal disease in patients whose tumors expressed the MAGE-A3 gene and were removed surgically. In Sep 2013, Glaxo had announced that the phase III DERMA study evaluating MAGE-A3 cancer immunotherapeutic in melanoma patients failed to meet its first co-primary endpoint.

The independent data monitoring committee (:IDMC) recommended continuation of the DERMA study until its second co-primary endpoint was evaluated. Data related to the second co-primary endpoint is expected in 2015.

With the NSCLC indication off the table and a failed melanoma study, our expectations from the MAGE-A3 cancer immunotherapeutic are at an all-time low.

Glaxo carries a Zacks Rank #4 (Sell). Some better-ranked stocks include Alexion Pharmaceuticals, Inc. (ALXN) and Alkermes (ALKS). Both carry a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on GSK
Read the Full Research Report on AGEN
Read the Full Research Report on ALXN
Read the Full Research Report on ALKS

Zacks Investment Research